Skip to main content

Table 1 Clinical data and cerebrospinal fluid (CSF) findings in Parkinson’s disease (PD) patients and controls

From: Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease

 

CTRL

IND

PD 1-2

PD 2.5-4

No. of patients

47

11

46

27

Age in years

60.4 ± 10.9 (45.0 to 83.0)

59.2 ± 9.0 (45.0 to 75.0)

60.3 ± 9.2 (44.0 to 77.0)

63.9 ± 10.1 (49.0 to 83.0)

Disease duration, months

-

-

25.8 ± 15.1

54.0 ± 41.7

UPDRS III score

-

-

19.0 ± 5.6

38.0 ± 10.6

H&Y stage

-

-

1.6 ± 0.4

3.0 ± 0.5

PD medications

-

-

None: 65.2%

None: 7.4%

   

DA: 19.6%

DA: 22.2%

   

LD: 4.3%

LD: 33.3%

   

LD + DA: 10.9%

LD + DA: 37.1%

Motor fluctuations

-

-

7/46

17/27

Albumin ratio (× 10-3)

5.2 (2.3 to 13.1)

5.8 (3.4 to 8.1)

5.6 (2.6 to 16.2)

8.2 (3.0 to 21.2)

IgG ratio (× 10-3)

2.7 (1.1 to 6.9)

2.8 (1.1 to 4.0)

2.7 (1.1 to 9.5)

3.9 (1.6 to 10.4)

  1. The top half of the table shows clinical data expressed as mean ± SD (minimum to maximum). The lower half shows biochemical values expressed as median (minimum to maximum).
  2. CTRL = control group of healthy subjects; DA = dopamine agonists; H&Y = Hoehn-Yahr; IND = independent group with no neurological disease; LD = levodopa; PD 1–2 = Parkinson’s disease patients with H&Y stage ranging from 1 to 2; PD 2.5-4 = Parkinson’s disease patients with H&Y stage ranging from 2.5 to 4; UPDRS = Unified Parkinson’s Disease Rating Scale.